Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 3
1987 1
1990 3
1991 2
1993 2
1994 1
1995 7
1996 3
1997 1
1998 2
1999 2
2000 2
2002 1
2003 1
2004 1
2005 3
2006 2
2007 1
2008 5
2009 4
2010 1
2013 4
2014 3
2015 3
2016 2
2017 2
2018 7
2019 7
2020 7
2021 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Pignata S, et al. Among authors: lauria r. Lancet Oncol. 2021 Feb;22(2):267-276. doi: 10.1016/S1470-2045(20)30637-9. Lancet Oncol. 2021. PMID: 33539744 Clinical Trial.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: lauria r. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A, Biganzoli L, Bordonaro R, Cinieri S, Conte P, Laurentis M, Mastro LD, Gori S, Lauria R, Marchetti P, Michelotti A, Montemurro F, Naso G, Pronzato P, Puglisi F, Tondini CA. Frassoldati A, et al. Among authors: lauria r. Future Oncol. 2020 Feb;16(5):129-145. doi: 10.2217/fon-2018-0942. Epub 2019 Dec 18. Future Oncol. 2020. PMID: 31849236 Review.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, Bergamini A, Corrado G, Perniola G, Cassani C, Savarese A, Gori S, Greco F, De Angelis C, Zafarana E, Giannarelli D, Cinieri S, Mosconi AM, Raspagliesi F, Pignata S, Scambia G, Lorusso D. Musacchio L, et al. Among authors: lauria r. Gynecol Oncol. 2024 Jan 25;184:24-30. doi: 10.1016/j.ygyno.2024.01.022. Online ahead of print. Gynecol Oncol. 2024. PMID: 38277918
Cochlear implants: Insertion assessment by computed tomography.
Menegatti Pavan AL, Alves AFF, Giacomini G, Altemani JMC, Castilho AM, Lauria RA, da Silva VAR, Guimarães AC, de Pina DR. Menegatti Pavan AL, et al. Among authors: lauria ra. Am J Otolaryngol. 2018 Jul-Aug;39(4):431-435. doi: 10.1016/j.amjoto.2018.04.009. Epub 2018 Apr 14. Am J Otolaryngol. 2018. PMID: 29685378
Epigenetic inactivation of the autophagy-lysosomal system in appendix in Parkinson's disease.
Gordevicius J, Li P, Marshall LL, Killinger BA, Lang S, Ensink E, Kuhn NC, Cui W, Maroof N, Lauria R, Rueb C, Siebourg-Polster J, Maliver P, Lamp J, Vega I, Manfredsson FP, Britschgi M, Labrie V. Gordevicius J, et al. Among authors: lauria r. Nat Commun. 2021 Aug 26;12(1):5134. doi: 10.1038/s41467-021-25474-x. Nat Commun. 2021. PMID: 34446734 Free PMC article.
EMPACT syndrome associated with phenobarbital.
Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, Bianca D, De Placido S, Ayala F. Fabbrocini G, et al. Among authors: lauria r. Dermatitis. 2013 Jan-Feb;24(1):37-9. doi: 10.1097/DER.0b013e31827ede32. Dermatitis. 2013. PMID: 23340399
Tumor characteristics and prognosis in familial breast cancer.
Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, Forestieri V, Giuliano M, De Angelis C, Montella M, Crispo A, De Placido S. Arpino G, et al. Among authors: lauria r. BMC Cancer. 2016 Nov 29;16(1):924. doi: 10.1186/s12885-016-2962-1. BMC Cancer. 2016. PMID: 27899083 Free PMC article.
84 results